NASDAQ$MDXG

Mimedx Group Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Reported net sales growth and improved financial profile.

MiMedx Group, Inc. announced its Q1 2023 results, featuring a 21.7% increase in net sales to $71.7 million compared to the prior year period. The company reported a net loss of $5.0 million and an Adjusted EBITDA of $5.5 million, driven by demand for new products and improved cost controls.

  • Net sales increased by 21.7% year-over-year to $71.7 million.
  • Net loss improved to $5.0 million, compared to $10.5 million in the prior year period.
  • Adjusted EBITDA was $5.5 million, a substantial increase from the prior year period's loss of $1.7 million.
  • Gross margin improved sequentially, reversing the trend from 2022.

Headline financials

Total Revenue

$71.7M

Previous: $58.9M+21.7%
EPS (adj)

-$0.06

Previous: -$0.11+45.5%
Adjusted EBITDA

$5.54M

No prior period
Gross Margin

82.7%

No prior period
Capital Expenditures

-$633K

Previous: -$118K-436.4%
Free Cash Flow

-$5.62M

Previous: -$10.6M+47.1%
Net Income

-$4.98M

Previous: -$10.5M+52.5%
Operating Income

-$3.38M

Previous: -$9.3M+63.6%
Gross Profit

$59.3M

Previous: $49M+21.0%
Cash & Equivalents

$61.2M

Previous: $75.7M-19.1%
Total Assets

$168M

Previous: $174M-3.6%
Stock-Based Comp

$3.9M

Previous: $4M-2.4%

Revenue & EPS history

Mimedx · Revenue · Quarterly

$71.7M

Q1 2023+21.7%vs Q1 2022
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Forward guidance

The Company anticipates sales growth in the low double-digits annually, driven by new product uptake, demand across service sites, and sales in Japan. They aim for a Wound & Surgical segment contribution margin at or above 30% of segment net sales and corporate expenses below 20% of sales.

Tailwinds

  • Continued uptake of new products
  • Solid demand across its sites of service
  • Ramping contributions from sales in Japan
  • Wound & Surgical segment contribution margin at or above 30% of segment net sales
  • Corporate expenses as a percentage of sales below 20%

Headwinds

  • Future sales are uncertain and are affected by competition and access to customers
  • Patient access to healthcare providers
  • The reimbursement environment
  • The results of scientific research are uncertain and may have little or no value
  • The effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+1.7%

Avg return

Earnings day

+2.9%

Avg return

5 days after

+7.2%

Avg return

30 days after

53%

34 / 64 earnings

Positive

+37.9%

Q1 2023

Best reaction

-23.3%

Q3 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-9.1%+6.2%+8.2%
Q4 2025-0.9%-8.8%-28.8%
Q3 2025+2.6%+7.0%-4.3%
Q1 2025-8.1%-3.9%-6.5%
Q4 2024+1.6%+1.1%-5.9%
Q3 2024+17.9%+22.7%+59.2%
Q2 2024-12.0%-17.7%-9.9%
Q1 2024+16.8%+17.7%+13.7%
Q4 2023-2.9%-1.7%-8.3%
Q3 2023+6.7%+10.9%+26.5%
Q2 2023-4.6%-4.2%-8.1%
Q1 2023+37.9%+49.1%+50.4%
Q4 2022-11.4%-6.4%-29.0%
Q3 2022-3.6%+1.3%+12.6%
Q2 2022+8.2%+15.5%+2.3%
Q1 2022+11.1%-8.9%-4.8%
Q4 2021+1.4%-1.6%-4.0%
Q3 2021+18.8%+22.6%+2.5%
Q2 2021-2.5%+1.4%+23.4%
Q1 2021-2.9%-5.0%+2.0%
Q4 2020-15.3%-13.4%+13.8%
Q3 2020+3.4%-8.2%-5.6%
Q2 2020+2.3%+4.2%+14.4%
Q2 2018+8.2%+3.2%+18.2%
Q1 2020+8.2%+3.2%+18.2%
Q4 2018+8.2%+3.2%+18.2%
Q4 2019+8.2%+3.2%+18.2%
Q2 2019+8.2%+3.2%+18.2%
Q1 2018+8.2%+3.2%+18.2%
Q1 2019+8.2%+3.2%+18.2%
Q3 2019+8.2%+3.2%+18.2%
Q4 2017-21.6%-22.1%-14.0%
Q3 2018-1.3%-8.6%-7.0%
Q3 2017+4.1%+8.7%-4.9%
Q2 2017+0.7%+2.1%+5.9%
Q1 2017+8.2%+19.1%+17.5%
Q4 2016-3.9%+3.4%+9.8%
Q3 2016+4.9%+8.0%+19.1%
Q2 2016-0.9%-1.7%-5.6%
Q1 2016-1.4%
Q4 2015-0.4%
Q3 2015-23.3%
Q2 2015-13.5%
Q1 2015+0.9%
Q4 2014+8.7%
Q3 2014+13.2%
Q2 2014+5.5%
Q1 2014-3.8%
Q4 2013+2.2%
Q3 2013-3.5%
Q2 2013+0.8%
Q1 2013-2.2%
Q4 2012+8.5%
Q3 2012+13.5%
Q2 2012-4.8%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011-4.2%
Q2 2011-2.5%
Q1 2011-3.7%
Q4 2010+5.8%
Q3 2010+0.0%
Q2 2010-4.8%
Q1 2010+4.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro